SCHEMBL13629290

SCHEMBL13629290

CCc1ccc(NS(=O)(=O)c2ccc(F)cc2Cl)cc1F

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 3/20 0.52
PFKFB3 Q16875 1/20 0.47
HTR6 P50406 2/20 0.47
FABP4 P15090 2/20 0.46
FABP5 Q01469 2/20 0.46
PPARG P37231 1/20 0.44
SGK1 O00141 4/20 0.44
CCR2 P41597 1/20 0.42
HSD17B3 P37058 1/20 0.42
HSD17B2 P37059 1/20 0.42
THRB P10828 1/20 0.42
HPGD P15428 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ITGA1 P56199 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13629411 0.90 PPARG (0.55) PPARGCCR2ITGA1ALDH1A1MAPT
SCHEMBL13629339 0.88 BRD4 (0.51) BRD4PFKFB3HTR6FABP4FABP5
SCHEMBL13629338 0.85 SLC22A12 (0.53) BRD4ALDH1A1
SCHEMBL13629408 0.85 CDK1 (0.51) BRD4PPARGSGK1
SCHEMBL13629466 0.84 BRPF1 (0.46) PPARG
SCHEMBL13615216 0.82 BRD4 (0.52) BRD4PFKFB3HTR6FABP4FABP5
SCHEMBL13629296 0.82 ALDH1A1 (0.57) HPGDSMN1; SMN2ALDH1A1MAPT
SCHEMBL13629312 0.81 ALDH1A1 (0.58) SGK1THRBHPGDALDH1A1
Propane SCHEMBL7213006 0.79 CA1 (0.49) BRD4PFKFB3HTR6FABP4FABP5
SCHEMBL13629427 0.78 ALDH1A1 (0.54) THRBALDH1A1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK BRD4 548/4885PFKFB3 482/4885HTR6 1515/4885
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK BRD4 674/4885PFKFB3 467/4885HTR6 1455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.